RNA Sequencing Analysis May Hold the Key to More Accurate Diagnosis and Targeted Treatment of Pediatric B-Acute Lymphoblastic Leukemia
Philadelphia | January 29, 2024
Pilot study by Children’s Hospital Los Angeles and City of Hope proposes a promising global, clinically applicable genomic assay for the diagnosis and treatment of this heterogeneous leukemia, reports The Journal of Molecular Diagnostics
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, representing more than 30% of all pediatric cases. A pilot study(opens in new tab/window) in The Journal of Molecular Diagnostics(opens in new tab/window), published by Elsevier, confirms the feasibility of implementing an RNA sequencing analysis (RNA-Seq) workflow for clinical diagnosis of molecular subtypes in pediatric B-acute lymphoblastic leukemia (B-ALL). This promising and cost-efficient global genomic assay for B-ALL may lead to more accurate diagnosis as well as targeted treatment options.
ALL comprises a constellation of diverse molecular subtypes, each with their own individual drug sensitivity pattern, treatment response, and even prognosis. It is important to identify specific subtypes, particularly in the current era of personalized medicine. However, identification requires an array of profiling tools, making the process laborious and expensive.
Co-lead lead investigator Gordana Raca, MD, PhD, Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, explains, “The goal of the study was to address limitations of current standard-of-care (SOC) testing for pediatric B-ALL, which cannot identify multiple recently discovered subtypes of the disease. We also wanted to take advantage of expression data generated by the enrichment-based RNA-Seq assay clinically validated in our laboratory(opens in new tab/window) for detection of oncogenic fusions in cancer to evaluate if additional data analyses could help determine subtype classification in addition to fusion information for our B-ALL cases.”
Investigators reviewed archival clinical, morphologic, immunophenotypic, and molecular data as well as residual DNA, RNA, and frozen bone marrow aspirate and/or leukemic peripheral blood samples from previous clinical testing in a group of 76 pediatric patients. Results were analyzed from 61 newly diagnosed patients and 25 patients who had relapsed/refractory B-ALL who underwent cytogenetic and molecular characterization as part of their standard clinical care at the Center for Personalized Medicine at Children’s Hospital Los Angeles between March 2016 and September 2020. They hypothesized that RNA-Seq, which has been used in the discovery of novel molecular subtypes of B-ALL, could also be a clinically useful tool for diagnostic classification of B-ALL cases.
To test this hypothesis investigators analyzed RNA-Seq data in 28 cases of B-ALL with known subtype and 48 with undetermined subtype following clinical karyotype analysis, fluorescence in situ hybridization, chromosomal microarray, and next-generation sequencing DNA and RNA fusion panel testing (OncoKids®). RNA-Seq analysis accurately identified the subtypes in all 28 known cases and determined the genetic subtype in 38 of the 48 previously unknown cases (79%). RNA-Seq analysis was also able to detect oncogenic fusions, large copy number abnormalities, oncogenic hot-spot sequence variants, and intragenic IKZF1 deletions.
Co-Lead investigatorZhaohuiGu, PhD, Department of Computational and Quantitative Medicine & Systems Biology, Beckman Research Institute of City of Hope, Duarte, says, “The study showed that B-ALL cases with known subtypes by SOC testing were fully concordant with the RNA-Seq–based classification. In addition, RNA-Seq analysis allowed us to successfully classify a large proportion of cases that remained unknown upon comprehensive SOC testing. RNA-Seq–based classification was relatively easy to implement in a medium-size academic laboratory using data from a clinically validated fusion assay.”
Dr. Raca adds, “RNA-Seq analysis enables accurate determination of the genetic subtype for an increased proportion of pediatric B-ALL cases, which will allow more accurate risk stratification and optimization of patient management. Accurate subtype determination at diagnosis will also grow our knowledge about morphologic, immunophenotypic, and clinical characteristics of novel B-ALL subtypes. We were surprised by a relatively high frequency of some novel B-ALL subtypes (like PAX5Alt and DUX4) in our patient cohort, which remain undiagnosed by SOC testing. The study also resulted in discovery of several previously unreported fusions.”
Dr. Raca says, “The study showed that expression-profile–based classification, which to date has been mostly used in research, can also be a very powerful clinical assay for pediatric B-ALL. As a single test, it allows subtype determination in a higher proportion of cases than comprehensive multi-modal SOC testing performed at our institution. Therefore, it has the potential to increase both diagnostic yield and efficiency of B-ALL testing.”
In an accompanying editorial(opens in new tab/window), Shawn H.R. Lee, MD, Khoo Teck Puat–National University Children’s Medical Institute, National University Health System, Singapore, and Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, concurs that RNA-seq is arguably one of the most—or even potentially the most—powerful single tool for somatic profiling in pediatric B-ALL. However, he also notes that it still remains contentious whether RNA-Seq as the sole means of classification is recommended for all cases given some inherent limitations, especially in locations where analytical pipelines may not be as robust.
Dr Lee comments, “Overall, RNA-seq as a single somatic genomic ALL diagnostic platform holds immense promise, although still with associated gaps. In some cases, validation of positive cases by an alternative method (such as oncogene fusion test and DNA sequencing) may still be arguably a sounder approach. The test needs further refining to comprehensively obtain mutation information beyond that of molecular subtyping to make it globally accessible. As we move further into the era of precision medicine, the information provided by this test holds excellent promise in guiding relevant and risk-stratified treatment in this childhood cancer.”
Notes for editors
The article is “Transcriptome Sequencing Allows Comprehensive Genomic Characterization of Pediatric B-Acute Lymphoblastic Leukemia in an Academic Clinical Laboratory,” by Zunsong Hu, Alexandra E. Kovach, Venkata Yellapantula, Dejerianne Ostrow, Andrew Doan, Jianling Ji, Ryan J. Schmidt, Zhaohui Gu, Deepa Bhojwani, and Gordana Raca (https://doi.org/10.1016/j.jmoldx.2023.09.013(opens in new tab/window)).The article is openly available at https://www.jmdjournal.org/article/S1525-1578(23)00265-9/fulltext(opens in new tab/window).
The study was supported by Children’s Hospital Los Angeles Department of Pathology and Laboratory Medicine Translational Research Fund interdisciplinary research grant; the Beckman Research Institute of the City of Hope Research Start-Up Budget; the Leukemia and Lymphoma Society Special Fellow Award; NIH/National Cancer Institute Pathway to Independence Award R00 CA241297; Andrew McDonough B+ Childhood Cancer Research grant; Leukemia Research Foundation New Investigator grant; and The V Foundation for Cancer Research V Scholar Award.
The editorial is “Toward a Comprehensive One-Stop Shop for Somatic Genomic Profiling in Childhood Acute Lymphoblastic Leukemia,” by Shawn H.R. Lee (https://doi.org/10.1016/j.jmoldx.2023.11.001(opens in new tab/window)). The editorial is openly available at https://www.jmdjournal.org/article/S1525-1578(23)00266-0/fulltext(opens in new tab/window).
The articles appear in The Journal of Molecular Diagnostics, volume 26, issue 1 (January 2024), published by Elsevier.
Full text of these articles and additional information are available to credentialed journalists upon request; contact Eileen Leahy at +1 732 406 1313 or [email protected](opens in new tab/window). Journalists wishing to interview Gordana Raca, MD, PhD, should contact Marlen Bugarin at +1 323 361 5567 or [email protected](opens in new tab/window). To reach Shawn H.R. Lee, MD, for comment contact [email protected](opens in new tab/window).
About The Journal of Molecular Diagnostics
The Journal of Molecular Diagnostics(opens in new tab/window), the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. www.jmdjournal.org(opens in new tab/window)
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses.
Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, medical education, and nursing education. Researchers and healthcare professionals rely on over 2,900 digitized journals, including The Lancet(opens in new tab/window) and Cell(opens in new tab/window); 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation(opens in new tab/window) and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX(opens in new tab/window), a global provider of information-based analytics and decision tools for professional and business customers.